Oramed Pharmaceuticals Inc.
Oramed Pharmaceuticals Inc.
Your view on ORMP
Overview
What the company does, where it operates, and who runs it.
About Oramed Pharmaceuticals Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Nadav Kidron
- Headquarters
- 1185 Avenue of the Americas, New York City, NY, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Nadav Kidron
- Headquarters
- 1185 Avenue of the Americas, New York City, NY, US
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides.
Its proprietary flagship product is the ORMD-0801, an orally ingestible insulin capsule, which completed phase II clinical trials for the treatment of individuals with diabetes.
It is also developing ORMD-0901, an oral glucagon-like peptide-1 capsule that has completed phase I clinical trials for the treatment of type 2 diabetes; and a weight loss treatment in the form of an oral leptin capsule.
The company was formerly known as Integrated Security Technologies, Inc. and changed its name to Oramed Pharmaceuticals Inc. in April 2006. Oramed Pharmaceuticals Inc. was founded in 2002 and is based in New York, New York.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Oramed Pharmaceuticals Inc., and the rating behind it. ORMP last traded at $4.08, 1.0× trailing earnings — the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Oramed Pharmaceuticals Inc.. Starting points for Oramed Pharmaceuticals Inc.: P/E 1.0, EPS $4.26, beta 1.28 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Oramed Pharmaceuticals Inc.. Oramed Pharmaceuticals Inc. paid $0.25 per share over the last year — a 6.1% yield at the current $4.08 price. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Oramed Pharmaceuticals Inc.. Trailing twelve-month EPS for Oramed Pharmaceuticals Inc. stands at $4.26. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Oramed Pharmaceuticals Inc.. Oramed Pharmaceuticals Inc. has reported as a listed company since 2007. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Oramed Pharmaceuticals Inc. valued side by side against its closest peers. Oramed Pharmaceuticals Inc. is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Oramed Pharmaceuticals Inc., and how their positions are changing. At a $169.7M market value, institutional positions materially move Oramed Pharmaceuticals Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Oramed Pharmaceuticals Inc. executives and directors. Shares of Oramed Pharmaceuticals Inc. have traded between $1.82 and $3.09 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Oramed Pharmaceuticals Inc.. Oramed Pharmaceuticals Inc. is a $169.7M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Oramed Pharmaceuticals Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Oramed Pharmaceuticals Inc.. Coverage tracks Oramed Pharmaceuticals Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.
Comments
Comments and replies from FRC members about this company.